Stocks and Investing
Stocks and Investing
Colin Bristow Initiated (BTAI) at Strong Buy and Held Target at $18 on, Apr 2nd, 2018
Colin Bristow of UBS, Initiated "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy and Held Target at $18 on, Apr 2nd, 2018.
Colin, nor any peers, have made any analyst calls on BTAI in the last 4 months.
Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30